Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic User Fees: FDA Goes On Backlog Offensive

This article was originally published in The Pink Sheet Daily

Executive Summary

Officials remind industry what the formal GDUFA backlog entails and says agency is exceeding expectations for review.


Related Content

'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA
User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases
Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending
ANDA Submission Wave Continues; Is A Crest Near?
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts